Hemophilia A patients who develop inhibitors — neutralizing antibodies made by immune cells against clotting factors — have more…
Articles by Marisa Wexler, MS
Prophylactic, or preventive, treatment with an experimental replacement therapy called TQG202 safely maintained a low bleeding rate in people with…
The U.S. Food and Drug Administration (FDA) has granted priority review for the approval of efanesoctocog alfa, with a…
The European Commission has granted conditional marketing authorization to BioMarin’s one-time gene therapy Roctavian (valoctocogene roxaparvovec) as a treatment…
Treatment with Hemlibra (emicizumab) improved joint health in people with hemophilia A participating in the Phase 3 HAVEN…
Older men with hemophilia report higher rates of anxiety, depression, and diabetes compared with the general U.S. population, a…
Switching to Hemlibra (emicizumab) can add more than $100,000 a year to healthcare costs for people with hemophilia…
The extended half-life replacement therapies Eloctate and Alprolix can be used to effectively manage bleeding during surgery in people with…
A single dose of Freeline Therapeutics’ experimental gene therapy FLT180a increased the levels of factor IX (FIX) — the…
Most people with hemophilia A or B who switched from an approved prophylactic (preventive) therapy regimen to once-monthly…